Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492101 · ClinicalTrials.gov registry record · Phase 3
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
A Phase 3 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 852
- Enrollment target
NCT01492101: Completed Phase 3 study, sponsored by Nektar Therapeutics.
NCT01492101 is a Phase 3 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 852 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492101, a Phase 3 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 852 participants
- Enrollment target
Study Summary
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.
Primary Outcome
Duration of OS was defined as the time from the date of randomisation to the date of death due to any cause. Subjects were followed until their date of death, loss to follow-up, withdrawal of consent for further follow-up for survival, or final database closure. OS was determined using the ITT population which included all subjects randomized into 1 of the 2 treatment arms. Subjects who were lost-to-follow-up or were not known to have died were censored at last date they were shown to be alive.
Interventions
- DRUG NKTR-102
- DRUG Treatment of Physician's Choice (TPC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
What the finished NCT01492101 record still lists
NCT01492101 is an interventional study that assigns participants to a tested intervention. The registered 852 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which NKTR-102 is the first listed.
NCT01492101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01492101 about?
NCT01492101 is a clinical study titled "The BEACON Study (Breast Cancer Outcomes With NKTR-102)". The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who ...
What is the current status of trial NCT01492101?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 852 participants. The study started on 2011-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01492101?
The interventions under investigation include: NKTR-102 (DRUG), Treatment of Physician's Choice (TPC) (DRUG).
Who is sponsoring clinical trial NCT01492101?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01492101's enrollment target sits among peer trials
852 385th of 2000 higher than 1,615 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia